Abstract: A drone deployment system of this disclosure includes an enclosed cargo bay or space including at least one wall having at least one section moveable between a closed position and an opened position; and a launch platform adapted for use with one or more drones, the launch platform housed by the enclosed cargo bay and located opposite the at least one section, the launch platform moveable between a stowed and a deployed elevation, angular orientation, or elevation and angular orientation. The enclosed cargo bay may be armored. When in the opened position, the opening provides a space through which the one or more drones may be launched. In some embodiments, the at least one section is slidable. In other embodiments, the section is pivotable. Embodiments of this disclosure provide for transport, launch and recovery of drones from remote areas as well as service and charging of drones in remote areas.

Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.

Abstract: Methods for identifying antigens as potential biomarkers for the early detection of ovarian cancer, as well as kits for utilizing said antigens as biomarkers and in personalized medicine/therapeutics assessment. Protein microarrays displaying full-length candidate antigens were developed and sequentially screening to select candidate autoantibody biomarkers to limit the false discovery rate inherent to large-scale proteomic screening.

Abstract: The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.

Abstract: The invention is directed to assays of CA-125 immune complexes that can be used diagnostically. It also includes glass or plastic plates or slides on which the monoclonal antibodies against CA-125 have been immobilized and kits containing these plates or slides.

Abstract: The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.

Abstract: The present invention is directed to pharmaceutical compositions and nutritional supplements that contain large amount of ginkgolides, particularly ginkgolide A or B, and for which, the other components normally found in Ginkgo biloba extracts have been removed. The compositions may be administered to women to prevent or treat ovarian cancer, particularly non-mucinous ovarian cancer.

Abstract: The present invention is directed to diagnostic methods based upon the expression of the protein osteopontin. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer.